

1 Adam Hosmer-Henner (ISBN 12779)
2 Philip Mannelly (ISBN 14236)
3 Chelsea Latino (ISBN 14227)
4 McDONALD CARANO LLP
5 100 W. Liberty Street, Tenth Floor
Reno, NV 89501
(775) 788-2000
ahosmerhenner@mcdonaldcarano.com
pmannelly@mcdonaldcarano.com
clatino@mcdonaldcarano.com

3 Margaret A. McLetchie (NSBN 10931)
4 Alina Shell (NSBN 11711)
5 McLETCHIE LAW
6 701 E. Bridger Ave., Suite 520
7 Las Vegas, NV 89101
8 (702) 728-5300
9 maggie@nvlitigation.com
10 alina@nvlitigation.com

11 || *Class Counsel*

**UNITED STATES DISTRICT COURT
DISTRICT OF NEVADA**

IN RE: HCV PRISON LITIGATION

Case No: 3:19-cv-00577-MMD-CLB

RESPONSE TO QUARTERLY REPORT

20 Class Counsel submits this Response to Quarterly Report (ECF No. 86) to advise the Court
21 of several matters related to the implementation of the Consent Decree (ECF No. 80) that have
22 been raised between the parties but which are still of potential concern to Class Counsel.

MEMORANDUM OF POINTS AND AUTHORITIES

24 | I. INTRODUCTION

25 Six months after the Effective Date of the Consent Decree, Defendants have successfully
26 tested all class members for HCV that were in NDOC custody as well as screened and prioritized
27 all class members according to the revised MD 219. (ECF No. 86). Additionally, Defendants
28 provided DAA treatment to 140 of the 168 Priority 1 class members by April 29, 2021, with the

1 balance awaiting the arrival of their medication or further medical testing. It does not appear that
2 any class members have been denied DAA treatment for non-medical reasons.

3 However, Class Counsel have raised concerns about 1) the relatively low incidence of HCV
4 that has been identified and 2) the rate of treatment of class members with HCV with respect to
5 future deadlines. The parties have held conference calls on several occasions to discuss these issues
6 and Defendants have provided supplemental information. Class Counsel believes that it is
7 important to flag these issues for the Court now to prevent and hopefully avert surprise at the
8 twelve-month mark.

9 **II. KNOWN INCIDENCE OF HCV**

10 Based on discovery responses and estimates provided by Defendants, Class Counsel
11 expected the number of class members with HCV in NDOC custody to total approximately 2,400.
12 (ECF No. 86 ¶ 35) (“Defendants represent and warrant that, to the best of their current knowledge,
13 as of the Effective Date there are fewer than 2,400 inmates in NDOC custody who have chronic
14 HCV”). As of March 11, 2020, Defendants had identified 1,114 class members in NDOC custody
15 that had been diagnosed with HCV and this number was based on only partial testing of the inmate
16 population. Additionally, epidemiologic studies estimated the prevalence of HCV infection in
17 incarcerated populations as falling between 17.4% to 23.1%. *HCV Testing and Treatment in*
18 *Correctional Settings*, American Association for the Study of Liver Diseases and Infectious
19 Diseases Society of America (available at [https://www.hcvguidelines.org/unique-](https://www.hcvguidelines.org/unique-populations/correctional)
20 [populations/correctional](https://www.hcvguidelines.org/unique-populations/correctional)) (citing to Varan, A.K., et al., *Hepatitis C Seroprevalence among Prison*
21 *Inmates since 2001: Still High but Declining*, Public Health Reports, 2014:129, 187-195). Based
22 on the inmate population on April 6, 2021 of 10,753, these studies would predict that between
23 1,871 and 2,484 class members in NDOC custody would have HCV. However, as of April 29,
24 2021 only a total of 736 class members have been confirmed by Defendants to have HCV.

25 The total of 736 class members is surprising because Defendants have not treated 378 class
26 members (the difference between 1,114 and 736) with DAA treatment since March 11, 2020 and
27 because Defendants have tested 13,073 inmates as of April 29, 2021, and 806 inmates between
28 January 29, 2021 to April 13, 2021 alone. The parties have discussed several explanations for this

1 discrepancy, but the arithmetic, at least from Class Counsel's perspective, still does not pencil.
2 One potential explanation is the number of refusals of testing and treatment by the inmate
3 population. Defendants identified 1,743 class members who refused testing for HCV and 42 class
4 members who refused treatment for HCV. While these populations alone would likely not make
5 up the difference between the expected and the identified incidence of HCV, there may be a
6 disproportionate number of class members with HCV within the untested group.

7 In order to reduce the number of class members who opt-out of HCV testing, Class Counsel
8 have proposed the provision of additional information about HCV testing and treatment.
9 Defendants have agreed in principle to supplement their current literature, Exhibit 1, with
10 additional literature from the Centers for Disease Control that has been identified and suggested
11 by Class Counsel, Exhibit 2. Class Counsel do not believe that the current literature, which
12 cursorily discusses HCV as a disease, adequately informs class members about the benefits of
13 HCV testing and treatment. Class Counsel and Defendants have not reached an agreement on
14 whether or how to provide this supplemental information to the class members who have already
15 refused testing. Class Counsel believe that Defendants should provide this supplemental literature
16 and information to all class members who have refused testing due to the benefits to the individuals
17 and the prison population as a whole from increased testing and treatment. While inmates may
18 opt-out of HCV testing, Class Counsel believe that Defendants have an obligation to adequately
19 counsel these individuals about the nature and benefits of HCV testing and must devote sufficient
20 financial and professional resources to this effort.

21 **III. RATE OF TREATMENT**

22 The Consent Decree required that DAA treatment for HCV be provided to all Priority One
23 class members by April 29, 2021 unless medically contraindicated. (ECF No. 80, ¶ 36).
24 Additionally, a minimum of 1,200 class members must be provided with DAA treatment for HCV
25 by October 29, 2021. (ECF No. 80, ¶ 37).

26 For the three months between January 29, 2021, Defendants indicated that 85 class
27 members began DAA treatment and an additional 47 class members were on orders to begin DAA
28 treatment. (ECF No. 86, 4). Even excluding these 132 class members or the larger set of the 168

1 Priority One class members, Defendants still must treat 1,032 class members in the next six months
 2 after only treating a maximum of 168 class members in the first six months. Of course, Defendants
 3 would not have an obligation to reach the 1,200 figure if everyone in the class with HCV has been
 4 treated, but even the current identified population of 736 would leave Defendants with
 5 approximately 568 class members remaining to be treated in the next six months.¹ This would
 6 require a rate of treatment 3.4 times higher than in the first six-month period.² While Defendants
 7 have expressed confidence to Class Counsel that the numbers will be reached and have offered
 8 some explanations for why the rate of treatment will increase in the next six months, Class Counsel
 9 remain skeptical.

10 If all current class members with HCV receive DAA treatment, then Class Counsel would
 11 suggest that the provisions of Paragraph 38 of the Consent Decree should go into effect such that
 12 Defendants would “provide DAA treatment to Class Members within NDOC’s custody at a rate
 13 that, at a minimum, exceeds the HCV infection rate of new inmates who test HCV positive, or who
 14 are confirmed to be HCV positive during the intake process.” (ECF No. 80, ¶ 38).

15 **IV. ADDITIONAL MATTERS**

16 Class Counsel have reviewed the Notice of Violation of Consent Decree filed on May 10,
 17 2021. (ECF No. 87). This individual does not appear on the lists of inmates who have tested
 18 positive for HCV that have been provided to Class Counsel. Class Counsel do

19 //

20 //

21 //

22 //

23 //

24

25 ¹ Class Counsel is also aware of circumstances where an inmate’s symptoms were previously not
 26 considered severe enough to warrant treatment prior to the Consent Decree, but have now
 27 progressed to the point where they are now too severe to receive treatment. This technically
 28 reduces the number of inmates eligible for treatment, but much more significantly underscores the
 need for the rapid provision of treatment to all eligible class members.

² Defendants did prioritize Priority One class members for treatment, but at the expense of the
 other categories of class members, none of whom received treatment during the prior six months.

1 not intend to take further action with respect to the Notice of Violation of Consent Decree at this
2 time.

3 Dated May 14, 2021.

4 McDONALD CARANO LLP

5 /s/ Adam Hosmer-Henner
6 Adam Hosmer-Henner, Esq. (NSBN 12779)
7 Philp Mannelly, Esq. (NSBN 14236)
8 Chelsea Latino, Esq. (NSBN 14227)
9 100 W. Liberty Street, Tenth Floor
10 Reno, NV 89501
11 (775) 788-2000
12 ahosmerhenner@mcdonaldcarano.com
13 pmannelly@mcdonaldcarano.com
14 clatino@mcdonaldcarano.com

15 Margaret A. McLetchie (NSBN 10931)
16 Alina Shell (NSBN 11711)
17 McCLETCHE LAW
18 701 E. Bridger Ave., Suite 520
19 Las Vegas, NV 89101
20 (702) 728-5300
21 maggie@nvlitigation.com
22 alina@nvlitigation.com

23 *Attorneys for Plaintiffs*

INDEX OF EXHIBITS

EXHIBIT #	DESCRIPTION	NUMBER OF PAGES
1	HCV Intake Form	2
2	CDC Pamphlets	3